Clinical trials: Ticagrelor
Acute Coronary Syndrome, Chronic Kidney Disease
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
A 4 week-duration cross-over study on Ticagrelor and Clopidogrel for the Acute Coronary Syndrome (ACS) and Chronic Kidney Disease (CKD) subjects, focusing on the platelet inhibition and safety observation.
- Conditions
- Acute Coronary Syndrome, Chronic Kidney Disease, End-Stage Renal Disease
- Trial name
- APROVE-CKD (NCT02459288)
- Testing
- Clopidogrel first, Ticagrelor first
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Ping-Yen Liu
Stable Coronary Syndrome, Percutaneous Coronary Intervention
A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND PILOT STUDY)
In patients with heart attacks, the current standard of care is to restore blood flow through percutaneous coronary intervention (PCI). This is done using stents (metal meshes) that opens up blockages.
- Conditions
- Stable Coronary Syndrome, Percutaneous Coronary Intervention, Antiplatelet Therapy, Ticagrelor
- Trial name
- NCT03224923
- Testing
- Ticagrelor 60mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Coronary Artery Disease
High Ticagrelor Loading Dose in STEMI
Ticagrelor is a reversible direct acting P2Y12 antagonist, which has shown to be superior to clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic events.
- Trial name
- NCT01898442
- Testing
- Ticagrelor 180mg, Ticagrelor 270mg, Ticagrelor 360mg
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Florida
Treatment of Acute Coronary Syndrome (ACS).
REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.
REWINDER is a multinational, multicentre, non-interventional, retrospective study of patients treated with an oral antiplatelet (ticagrelor, prasugrel or clopidogrel) while in hospital after an acute coronary syndrome (ACS)…
- Trial name
- REWINDER (NCT02190123)
- Testing
- ACS patients treated with OAP
- Where
- 15 sites in Belgium
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction
Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction
The purpose of the IMPRESSION study is to determine whether intravenous administration of morphine prior to ticagrelor administration in ST-segment elevation myocardial infarction (STEMI) patients and in non-ST-segment elevation…
- Conditions
- ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, VA Drug Interactions
- Trial name
- IMPRESSION (NCT02217878)
- Testing
- Morphine, Ticagrelor
- Where
- Poland
- Volunteers
- 74 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Acute Coronary Syndrome
RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy
This NIS is a multi-centre, observational, descriptive, cross-sectional study including all consecutive patients with Acute Coronary Syndrome (ACS) and a single-arm, prospective, longitudinal cohort study which will include…
- Trial name
- STREAM (NCT02288260)
- Where
- 15 sites in Russia
- Volunteers
- 5,470 people
- Sponsor
- AstraZeneca
ST-segment Elevation Myocardial Infarction
Rapid Activity of Platelet Inhibitor Drugs Study
The aim of the RAPID study is to assess the rapid onset of action of the 2 novel oral antiplatelet agents, Prasugrel and Ticagrelor, in 50 patients with STEMI undergoing PPCI with bivalirudin monotherapy.
- Trial name
- RAPID (NCT01510171)
- Testing
- Prasugrel, Ticagrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Careggi Hospital
Aortic Valve Stenosis
A Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During TAVI
Ticagrelor administered with Acetylsalicylic Acid (ASA) will provide better cerebral protection from microembolization in the cerebral circulation during Transcatheter Aortic Valve Implantation (TAVI) and 30 days afterwards, than…
- Trial name
- PTOLEMAIOS (NCT02989558)
- Testing
- Ticagrelor plus ASA, Clopidogrel plus ASA
- Where
- Greece
- Volunteers
- 90 people
- Sponsor
- University of Athens
Non ST Segment Elevation Acute Coronary Syndrome
Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy
Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent implantation.
- Trial name
- OPTICA (NCT04766437)
- Testing
- Prasugrel 10mg, Ticagrelor 90mg
- Where
- Netherlands
- Volunteers
- 75 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Coronary Artery Disease
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Polymorphisms of the cytochrome P450 (CYP) 2C19 enzyme has been consistently shown to modulate clopidogrel response. Accordingly, the Food and Drug Administration (FDA) has issued a warning on the potential for reduced efficacy…
- Trial name
- NCT03489863
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Florida
Coronary Artery Disease
A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin
The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of…
- Trial name
- NCT00528411
- Testing
- Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Migraine, Headache
Ticagrelor Therapy for RefrACTORy Migraine Study
This is a prospective, open-label, single-arm pilot study treating 40 subjects to assess the hypothesis that P2Y, G protein-coupled 12 (P2Y12) inhibition with Brilinta/ticagrelor (90 mg by mouth (PO) twice a day) reduces episodic…
- Conditions
- Migraine, Headache, Migraine Headache
- Trial name
- TRACTOR (NCT02518464)
- Testing
- Ticagrelor 90 mg twice per day
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Cardiovascular Disease, Stable Angina
Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI
Ticagrelor therapy has been shown to reduce the rates of cardiovascular events and all-cause mortality compared to clopidogrel therapy in patients with acute coronary syndromes (ACS).
- Conditions
- Cardiovascular Disease, Stable Angina, Myocardial Infarction, Coronary Artery Disease
- Trial name
- NCT02012140
- Testing
- ticagrelor
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- LifeBridge Health
Abdominal Aortic Aneurysm
The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion
Abdominal aortic aneurysm (AAA) is a major health problem and ruptured AAA is a common cause of death in Europe and North America.
- Trial name
- TicAAA (NCT02070653)
- Testing
- Ticagrelor
- Where
- Sweden
- Volunteers
- 145 people
- Sponsor
- Uppsala University
Acute Coronary Syndrome, Acute Myocardial Infarction
Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel
A total of 50 participants diagnosed with ACS (group A ticagrelor 180mg/d, n=25), group B (clopidogrel 75mg + rivaroxaban 5mg/ d, n=25)) were consecutively enrolled and treated with study drugs on top of aspirin (100mg/d) for 1…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina
- Trial name
- NCT03481257
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease, CABG
The 10-Year Extended Follow-up of the DACAB Trial
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial.
- Conditions
- Coronary Artery Disease, CABG, Antiplatelet Therapy of Coronary Artery Bypass
- Trial name
- DACAB-FE-10Y (NCT07480629)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Acute Coronary Syndromes
A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta
To identify the following items through the post marketing surveillance under routine clinical practice after marketing authorization of Brilinta Tablet: the occurrence of unrevealed Serious Adverse Events (SAEs), current status…
- Trial name
- NCT01611272
- Where
- 23 sites in South Korea
- Volunteers
- 3,402 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants
The purpose of this study is to measure the effect of ticagrelor on the pharmacokinetics (PK) of rosuvastatin in healthy participants.
- Trial name
- NCT06554821
- Testing
- Rosuvastatin, Ticagrelor
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Myocardial Infarction, ST Segment Elevation Myocardial Infarction (STEMI)
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
This is a prospective randomized study, which investigates the coronary microvascular function as assessed by coronary angiography after administration of ticagrelor compared with clopidogrel in patients with myocardial…
- Trial name
- MIRTOS (NCT02429271)
- Testing
- Ticagrelor, Clopidogrel, Percutaneous Coronary Intervention (PCI)
- Where
- Greece
- Volunteers
- 336 people
- Sponsor
- Hellenic Cardiovascular Research Society
Coronary Artery Disease
Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS).
- Trial name
- NCT02514642
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University